Aroa is unlocking regenerative healing, accessability and affordabilityFind out more
Reinforced Bioscaffolds combine the best of biologics and synthetics to address the current shortcomings in surgical ventral hernia repair solutions. Read more about Reinforced Bioscaffolds on the TelaBio website.
Find out more
Our focus is delivering better healing, everyday, everywhere for everybody. We strive to make a meaningful impact for patients, surgeons and clinicians. We deliver high quality, simple to…Find out more
Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC.
MALVERN, Pa., June 7, 2018 /PRNewswire/ -- TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that early outcomes from the company's post-market BRAVO (BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair) study evaluating OviTex 1S Permanent for the treatment of ventral hernias are being presented at the 2018 Abdominal Wall Reconstruction Conference taking place June 7 – 9 at the Grand Hyatt Washington in Washington, DC.
MALVERN, Pa., May 31, 2018 /PRNewswire/ -- TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that its partner Aroa Biosurgery, a soft-tissue repair company based in New Zealand that develops and manufactures medical products to improve healing, has been granted EC Certification (CE Mark) allowing for the commercial launch of OviTex RBSs in the European Union (EU).Continue reading
MANCHESTER, Conn. & AUCKLAND, New Zealand--(BUSINESS WIRE)--New Zealand biomedical company Aroa Biosurgery and United States medical products company Hydrofera are launching Appulse in North America.
The two companies have recently bought back their wound care businesses from Hollister Inc.